Table 3 |
||||||
|
WAY-169916 gene-profiling experiment with spleen from rat adjuvant arthritis model |
||||||
|
Av. control |
Av. CFA |
Av. CFA + WAY-169916 |
AFC CFA |
AFC WAY-169916 |
Inhibition by WAY-169916 (%) |
|
|
|
||||||
|
Transcription factors |
||||||
|
CCAAT/enhancer binding protein (C/EBP), beta |
16.8 |
39.8 |
19.6 |
2.37 |
0.49 |
87.6 |
|
NF-E2-related factor 2 |
14.2 |
30.3 |
19.6 |
2.13 |
0.65 |
66.2 |
|
Immune mediators |
||||||
|
Mast cell protease 2 |
5.3 |
11.8 |
5.9 |
2.20 |
0.50 |
91.4 |
|
Arachidonate 5-lipoxygenase-activating protein |
18.9 |
46.5 |
23.9 |
2.46 |
0.51 |
82.0 |
|
Chemokine-like factor 1 |
10.5 |
28.9 |
18.9 |
2.75 |
0.65 |
54.3 |
|
Phospholipase A2, group IIA |
33.8 |
71.7 |
60.3 |
2.12 |
0.84 |
30.0 |
|
Proteoglycan 2, bone marrow |
27.6 |
147.4 |
59.1 |
5.34 |
0.40 |
73.7 |
|
Immune related |
||||||
|
CD14 antigen |
15.9 |
32.3 |
19.1 |
2.04 |
0.59 |
80.2 |
|
Peptidoglycan recognition protein |
10.2 |
39.6 |
14.5 |
3.88 |
0.37 |
85.2 |
|
Lipopolysaccharide-binding protein |
3.3 |
10.2 |
4.4 |
3.10 |
0.43 |
83.6 |
|
IL-1 receptor, type II |
2.2 |
8.1 |
3.5 |
3.71 |
0.44 |
76.8 |
|
Defensin RatNP-3 precursor |
31.7 |
105.3 |
63.5 |
3.32 |
0.60 |
56.8 |
|
Suppressor of cytokine signalling 3 |
15.2 |
35.3 |
15.2 |
2.33 |
0.43 |
99.7 |
|
Complement component 3 |
13.3 |
28.4 |
24.2 |
2.14 |
0.85 |
27.6 |
|
Defensin NP-2 precursor |
58.9 |
166.6 |
102.8 |
2.83 |
0.62 |
59.3 |
|
Defensin NP-4 precursor |
54.1 |
164.9 |
104.7 |
3.05 |
0.64 |
54.3 |
|
Paired immunoglobulin-like receptor-B |
11.0 |
22.7 |
18.3 |
2.07 |
0.81 |
37.6 |
|
25 oligoadenylate synthetase |
24.6 |
51.4 |
24.8 |
2.09 |
0.48 |
99.2 |
|
Tumor necrosis factor receptor II |
7.3 |
15.8 |
8.9 |
2.18 |
0.56 |
81.0 |
|
S100 calcium-binding protein A8 (calgranulin A) |
52.2 |
184.5 |
91.5 |
3.54 |
0.50 |
70.3 |
|
S100 calcium-binding protein A9 (calgranulin B) |
144.9 |
382.7 |
242.1 |
2.64 |
0.63 |
59.1 |
|
Ficolin B |
42.3 |
121.1 |
74.7 |
2.86 |
0.62 |
58.9 |
|
Myelin and lymphocyte protein |
11.8 |
27.6 |
19.9 |
2.34 |
0.72 |
49.1 |
|
Protease |
||||||
|
Matrix metalloproteinase 9 |
2.0 |
8.4 |
3.5 |
4.24 |
0.42 |
75.8 |
|
Chymase 1 |
2.9 |
9.2 |
5.1 |
3.16 |
0.56 |
64.8 |
|
Transport |
||||||
|
Monocarboxylate transporter |
10.3 |
24.4 |
10.0 |
2.38 |
0.41 |
102.3 |
|
Lipocalin 2 |
16.3 |
55.3 |
33.0 |
3.39 |
0.60 |
57.1 |
|
Acute phase |
||||||
|
Haptoglobin |
10.5 |
37.5 |
12.9 |
3.58 |
0.34 |
90.9 |
|
Metabolism |
||||||
|
Uridine phosphorylase I |
8.9 |
32.8 |
9.1 |
3.68 |
0.28 |
99.3 |
|
Guanine deaminase |
17.8 |
39.5 |
20.7 |
2.21 |
0.52 |
86.9 |
|
Microsomal glutathione S-transferase 1 |
40.0 |
87.6 |
51.2 |
2.19 |
0.58 |
76.6 |
|
GTP cyclohydrolase 1 |
11.6 |
25.5 |
23.6 |
2.20 |
0.93 |
13.8 |
|
Hepatic steroid hydroxylase II A2 |
9.0 |
18.7 |
21.5 |
2.07 |
1.15 |
-29.0 |
|
Adhesion |
||||||
|
C-CAM4 protein |
11.5 |
24.5 |
16.0 |
2.12 |
0.65 |
65.6 |
|
Fibronectin 1 |
57.2 |
116.6 |
91.3 |
2.04 |
0.78 |
42.6 |
|
Unknown function |
||||||
|
Expressed sequence tag |
20.0 |
41.5 |
25.1 |
2.08 |
0.61 |
76.1 |
|
|
||||||
|
AFC, average fold change; Av., average; CFA, complete Freund's adjuvant. |
||||||
|
Keith et al. Arthritis Research & Therapy 2005 7:R427 doi:10.1186/ar1692 |
||||||
